Loading grant details…
Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)
| Funder | National Institutes of Health |
|---|---|
| Recipient Organization | Not specified |
| Country | USA |
| Start Date | Nov 18, 2024 |
| End Date | Jan 10, 2027 |
| Duration | 783 days |
| Number of Grantees | 1 |
| Data Source | Grants.gov |
| Grant ID | f4d5f64e-0b81-4634-b3c1-9993ef53c00c |
Grant Description
The goal of the proposed funding announcement is twofold, to promote preclinical and patient based studies examining the mechanism(s) through which incretin mimetics (including agonists or antagonists of GLP-1, GIP-1, or dual GLP-1/GIP-1 agents) impact cancer risk, and to draw talented scientists who understand the dynamic changes caused by these agents to investigate the mechanisms of how these agents influence cancer risk rather than shorter term outcomes such as weight loss and diabetes.
The data thus far suggests that these agents may increase the risk of some, while decreasing the risk of other obesity related cancers.
All Grantees
To be determined
Interested in applying for this grant?
Complete our application form to express your interest and we'll guide you through the process.
Apply for This GrantQuick Summary
Related Grants
